{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:06:04Z","timestamp":1778076364966,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011878","name":"Vlaamse regering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011878","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1110121N"],"award-info":[{"award-number":["1110121N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.coph.2021.06.011","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:50:18Z","timestamp":1628124618000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Treatment of severe alcoholic hepatitis: A systematic review"],"prefix":"10.1016","volume":"60","author":[{"given":"Lukas","family":"Van Melkebeke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannelie","family":"Korf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel A.","family":"Tsochatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Schalk","family":"van der Merwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jef","family":"Verbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.06.011_bib1","doi-asserted-by":"crossref","DOI":"10.3350\/cmh.2020.0196","article-title":"Predictors of steroid non-response and new approaches in severe alcoholic hepatitis","volume":"26","author":"Sarin","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib2","first-page":"2020","article-title":"Liver transplantation for alcohol-related liver disease (ARLD): an update on controversies and considerations","author":"Yadav","year":"2020","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib3","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"Association for the study of the liver E: EASL clinical practice guidelines: management of alcohol-related liver disease","volume":"69","author":"Thursz","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib4","first-page":"1","article-title":"Alcoholic liver disease","volume":"4","author":"Seitz","year":"2018","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.coph.2021.06.011_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.17235\/reed.2020.7242\/2020","article-title":"Alcoholic-related liver disease: pathogenesis, management and future therapeutic developments","volume":"112","author":"Argemi","year":"2020","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.coph.2021.06.011_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2018.10.026","article-title":"Current trials and novel therapeutic targets for alcoholic hepatitis","volume":"70","author":"Singal","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.06.011_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","article-title":"Alcoholic liver disease: mechanisms of injury and targeted treatment","volume":"12","author":"Louvet","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7326\/0003-4819-110-9-685","article-title":"Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial","volume":"110","author":"Carithers","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.coph.2021.06.011_bib10","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1053\/gast.1996.v110.pm8964410","article-title":"Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone","volume":"110","author":"Mathurin","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/0016-5085(80)90867-7","article-title":"Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy - PubMed","volume":"78","author":"Depew","year":"1980","journal-title":"Gastroenterolgy"},{"key":"10.1016\/j.coph.2021.06.011_bib12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.4103\/2141-9248.141562","article-title":"Pentoxifylline plus prednisolone versus pentoxifylline only for severe alcoholic hepatitis: a randomized controlled clinical trial","volume":"4","author":"Mandal","year":"2014","journal-title":"Ann Med Health Sci Res"},{"key":"10.1016\/j.coph.2021.06.011_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/gut.23.1.75","article-title":"Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis","volume":"23","author":"Theodossi","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.06.011_bib14","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/MCG.0000000000000585","article-title":"Corticosteroids versus pentoxifylline for severe alcoholic hepatitis","volume":"50","author":"Njei","year":"2016","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/MCG.0000000000000674","article-title":"Treatment of severe alcoholic hepatitis with corticosteroid, pentoxifylline, or dual therapy","volume":"51","author":"Lee","year":"2017","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib17","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 Days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib18","article-title":"Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis","volume":"2017","author":"Buzzetti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.06.011_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001511.pub4","article-title":"Glucocorticosteroids for people with alcoholic hepatitis","author":"Pavlov","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.coph.2021.06.011_bib20","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","article-title":"Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting","volume":"69","author":"Avila","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.06.011_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2018.02.022","article-title":"The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis","volume":"69","author":"Serst\u00e9","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib22","first-page":"152","article-title":"Infections in severe alcoholic hepatitis","volume":"30","author":"Karakike","year":"2017","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib23","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/lt.24986","article-title":"Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial","volume":"24","author":"Thompson","year":"2018","journal-title":"Liver Transplant"},{"key":"10.1016\/j.coph.2021.06.011_bib24","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/DDDT.S200147","article-title":"Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events","volume":"13","author":"Subedi","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.coph.2021.06.011_bib25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A\u00a0double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.06.011_bib26","article-title":"Safety and efficacy of infliximab in severe alcoholic hepatitis: a systematic review","volume":"11","author":"Majeed","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2021.06.011_bib27","first-page":"96","article-title":"Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis","author":"Dasarathy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.coph.2021.06.011_bib28","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/CAD.0000000000000832","article-title":"A\u00a0review of canakinumab and its therapeutic potential for non-small cell lung cancer","volume":"30","author":"Schenk","year":"2019","journal-title":"Anti Canc Drugs"},{"key":"10.1016\/j.coph.2021.06.011_bib29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.gtc.2018.01.005","article-title":"Modern management of acute liver failure","volume":"47","author":"Khan","year":"2018","journal-title":"Gastroenterol Clin N Am"},{"key":"10.1016\/j.coph.2021.06.011_bib31","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jhep.2010.05.030","article-title":"Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial","volume":"53","author":"Moreno","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A\u00a0randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib33","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis - a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib34","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib35","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N -Acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"Nguyen-Khac","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.06.011_bib36","first-page":"20","article-title":"Pentoxifylline in severe alcoholic hepatitis: a prospective, randomised trial","volume":"60","author":"Sidhu","year":"2012","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.coph.2021.06.011_bib37","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib38","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s10620-012-2097-4","article-title":"Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE Trial)","volume":"57","author":"Sidhu","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.coph.2021.06.011_bib39","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.01.040","article-title":"Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis","volume":"138","author":"Lebrec","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2013.276300","article-title":"Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial","volume":"310","author":"Mathurin","year":"2013","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.coph.2021.06.011_bib41","first-page":"227","article-title":"Pentoxifilina versus esteroide en la sobrevivencia a corto plazo en hepatitis aguda alcoh\u00f3lica severa","volume":"28","author":"Garc\u00eda","year":"2012","journal-title":"Med Int Mex"},{"key":"10.1016\/j.coph.2021.06.011_bib42","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-De La Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib43","first-page":"32","article-title":"Hepatitis alcoh\u00f3lica grave: pentoxifilina como tratamiento de rescate en pacientes que no responden a esteroides","volume":"30","author":"Arredondo-Andrade","year":"2014","journal-title":"Med Int Mex"},{"key":"10.1016\/j.coph.2021.06.011_bib44","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3748\/wjg.15.1613","article-title":"Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial","volume":"15","author":"De","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2014.05.014","article-title":"Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: a randomised, non-inferiority, open trial - PubMed","volume":"61","author":"Park","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib46","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s12072-016-9751-4","article-title":"Prednisolone plus S-adenosil-l-methionine in severe alcoholic hepatitis","volume":"10","author":"Tkachenko","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1016\/j.coph.2021.06.011_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","article-title":"Gut-liver axis in alcoholic liver disease","volume":"148","author":"Szabo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib48","article-title":"Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury","author":"Wrzosek","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.coph.2021.06.011_bib49","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2018.10.019","article-title":"Microbiome as a therapeutic target in alcohol-related liver disease","volume":"70","author":"Sarin","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib50","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.coph.2021.06.011_bib51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial","volume":"32","author":"Cabr\u00e9","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.06.011_bib52","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.1840140624","article-title":"Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial - PubMed","volume":"14","author":"Mezey","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.06.011_bib53","doi-asserted-by":"crossref","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"Marot","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.coph.2021.06.011_bib54","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.coph.2021.06.011_bib55","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","article-title":"Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial","volume":"70","author":"Shasthry","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.06.011_bib56","article-title":"Efficacy of granulocyte colony stimulating factor in severe alcoholic hepatitis: a systematic review and meta-analysis","volume":"12","author":"Baig","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.coph.2021.06.011_bib57","first-page":"19","article-title":"Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial 11","author":"Cho","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.coph.2021.06.011_bib58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"Mathurin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.06.011_bib59","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s00423-018-1720-z","article-title":"Meta-analysis of patient survival and rate of alcohol relapse in liver-transplanted patients for acute alcoholic hepatitis","volume":"403","author":"Al-Saeedi","year":"2018","journal-title":"Langenbeck's Arch Surg"},{"key":"10.1016\/j.coph.2021.06.011_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190823","article-title":"Liver transplantation for alcoholic hepatitis: a systematic review with meta-analysis","volume":"13","author":"Marot","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.06.011_bib61","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0168-8278(88)80005-9","article-title":"Randomised controlled double-blind trial of the calcium channel antagonist amlodipine in the treatment of acute alcoholic hepatitis","volume":"28","author":"Bird","year":"1998","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.coph.2021.06.011_bib62","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/hep.21607","article-title":"The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids","volume":"45","author":"Louvet","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.coph.2021.06.011_bib63","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jhep.2018.11.005","article-title":"Endpoints and patient stratification in clinical trials for alcoholic hepatitis","volume":"70","author":"Mathurin","year":"2019","journal-title":"J\u00a0Hepatol"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221000849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:57:07Z","timestamp":1761461827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221000849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":63,"alternative-id":["S1471489221000849"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.011","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of severe alcoholic hepatitis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}